Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377: 1919-29. doi: 10.1056/NEJMoa1709937AntoniaSJVillegasADanielDVicenteDMurakamiSHuiRet alDurvalumab after chemoradiotherapy in stage III Non-Small-Cell Lung Cancer201737719192910.1056/NEJMoa1709937Open DOISearch in Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342-50. doi: 10.1056/NEJMoa1809697AntoniaSJVillegasADanielDVicenteDMurakamiSHuiRet alOverall survival with durvalumab after chemoradiotherapy in stage III NSCLC201837923425010.1056/NEJMoa1809697Open DOISearch in Google Scholar
Hui R, Ozguroglu M, Villegas A, Daniel D, Vicente D, Murakami S, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol 2019; 20: 1670–80. doi: 10.1016/S1470-2045(19)30519-4HuiROzgurogluMVillegasADanielDVicenteDMurakamiSet alPatient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study20192016708010.1016/S1470-2045(19)30519-4Open DOISearch in Google Scholar
Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JH, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC Trial. J Thorac Oncol 2021; 16: 860-7. doi: 10.1016/j.jtho.2020.12.015Faivre-FinnCVicenteDKurataTPlanchardDPaz-AresLVansteenkisteJHet alFour-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC Trial202116860710.1016/j.jtho.2020.12.015Open DOISearch in Google Scholar
Yusuf D, Walton RN, Hurry M, Farrer D, Bebb DG, Cheung WY, et al. Population-based treatment patterns and outcomes for stage III non–small cell lung cancer patients. Am J Clin Oncol 2020; 43: 615-20. doi: 10.1097/COC.0000000000000716YusufDWaltonRNHurryMFarrerDBebbDGCheungWYet alPopulation-based treatment patterns and outcomes for stage III non–small cell lung cancer patients2020436152010.1097/COC.0000000000000716Open DOISearch in Google Scholar
Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017; 8: 1-20. doi: 10.5306/wjco.v8.i1.1YoonSMShaikhTHallmanMTherapeutic management options for stage III non-small cell lung cancer2017812010.5306/wjco.v8.i1.1Open DOISearch in Google Scholar
Brierly DJ, Gospodarowicz MK, Witekind C, editors. TNM classification of malignant tumours. 8th edition. Oxford: Wiley-Blackwell; 2017. p. 114-20.BrierlyDJGospodarowiczMKWitekindCeditorsOxfordWiley-Blackwell;2017p114–20Search in Google Scholar
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143-52. doi: 10.1016/S1470-2045(17)30074-8SeymourLBogaertsJPerroneAFordRSchwartzLHMandrekarSet aliRECIST: guidelines for response criteria for use in trials testing immunotherapeutics201718e1435210.1016/S1470-2045(17)30074-8Open DOISearch in Google Scholar
NIH. National Cancer Institute. DCTD Division of Cancer Treatment & Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. U.S. Department of Health and Human Services; 2017. [cited 2021 Jul 07]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf2017[cited 2021 Jul 07]. Available athttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdfSearch in Google Scholar
Vrankar M, Zwitter M, Bavcar T, Milic A, Kovac V. Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial. Radiol Oncol 2014; 48: 369-80. doi: 10.2478/raon-2014-0026VrankarMZwitterMBavcarTMilicAKovacVInduction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial2014483698010.2478/raon-2014-0026423055725435850Open DOISearch in Google Scholar
Vrankar M, Stanic K. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiol Oncol 2018; 52: 281-8. doi: 10.2478/raon-2018-0009VrankarMStanicKLong-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy201852281810.2478/raon-2018-0009613736730210037Open DOISearch in Google Scholar
Vrankar M, Kern I, Stanic K. Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. Radiat Oncol 2020; 15: 247. doi: 10.1186/s13014-020-01696-zVrankarMKernIStanicKPrognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy20201524710.1186/s13014-020-01696-z759426733121520Open DOISearch in Google Scholar
Taugner J, Käsmann L, Eze C, Tufman A, Reinmuth N, Duell T, et al. Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC leads to significant improvement of local-regional control and overall survival in the real-world setting. Cancers 2021; 13: 1613. doi: 10.3390/cancers13071613TaugnerJKäsmannLEzeCTufmanAReinmuthNDuellTet alDurvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC leads to significant improvement of local-regional control and overall survival in the real-world setting202113161310.3390/cancers13071613803742933807324Open DOISearch in Google Scholar
Offin M, Shaverdian N, Rimner A, Lobaugh S, Shepherd AF, Simone CB 2nd, et al. Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. Radiother Oncol 2020; 149: 205-11. doi: 10.1016/j.radonc.2020.04.047OffinMShaverdianNRimnerALobaughSShepherdAFSimone CB 2nd, et alClinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab20201492051110.1016/j.radonc.2020.04.047823942832361014Open DOISearch in Google Scholar
Desilets A, Blanc-Durand F, Lau S, Hakozaki T, Kitadai R, Malo J, et al. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. Eur J Cancer 2021; 142: 83-91. doi: 10.1016/j.ejca.2020.10.008DesiletsABlanc-DurandFLauSHakozakiTKitadaiRMaloJet alDurvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study2021142839110.1016/j.ejca.2020.10.00833242835Open DOISearch in Google Scholar
Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, et al. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer 2020; 150: 114-22. doi: 10.1016/j.lungcan.2020.10.006FaehlingMSchumannCChristopoulosPHoffknechtPAltJHornMet alDurvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP)20201501142210.1016/j.lungcan.2020.10.00633126091Open DOISearch in Google Scholar
Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroğlu M, et al. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab on unresectable Stage III NSCLC (PACIFIC). Lung Cancer 2021; 151: 30-8. doi: 10.1016/j.lungcan.2020.11.024Faivre-FinnCSpigelDRSenanSLangerCPerezBAÖzgüroğluMet alImpact of prior chemoradiotherapy-related variables on outcomes with durvalumab on unresectable Stage III NSCLC (PACIFIC)202115130810.1016/j.lungcan.2020.11.02433285469Open DOISearch in Google Scholar
Jin G, Wang X, Xu C, Sun J, Yuan Z, Wang J, et al. Disparities in survival following surgery among patients with different histological types of N2-III non-small cell lung cancer: a Surveillance, Epidemiology and End Results (SEER) database analysis. Ann Transl Med 2020; 8: 1288. doi: 10.21037/atm-20-4357JinGWangXXuCSunJYuanZWangJet alDisparities in survival following surgery among patients with different histological types of N2-III non-small cell lung cancer: a Surveillance, Epidemiology and End Results (SEER) database analysis20208128810.21037/atm-20-4357766189233209868Open DOISearch in Google Scholar
Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R, et al. Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. J Thorac Oncol 2012; 7: 1479-84. doi: 10.1097/JTO.0b013e318267d032MorgenszternDWaqarSSubramanianJGaoFTrinkausKGovindanRet alPrognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 20032012714798410.1097/JTO.0b013e318267d03222982648Open DOISearch in Google Scholar
Wang BY, Huang JY, Chen HC, Lin CH, Lin SH, Hung WH, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol 2020; 146: 43–52. doi: 10.1007/s00432-019-03079-8WangBYHuangJYChenHCLinCHLinSHHungWHet alThe comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients2020146435210.1007/s00432-019-03079-831705294Open DOISearch in Google Scholar
Attili I, Tarantino P, Passaro A, Stati V, Curigliano G, de Marinis F. Strategies to overcome resistance to immune checkpoint blockade in lung cancer. Lung Cancer 2021; 154: 151-60. doi: 10.1016/j.lungcan.2021.02.035AttiliITarantinoPPassaroAStatiVCuriglianoGdeMarinis FStrategies to overcome resistance to immune checkpoint blockade in lung cancer20211541516010.1016/j.lungcan.2021.02.03533684660Open DOISearch in Google Scholar